Download by
Scanning QR Code
No Stock Yet
No Data
New Ray Shareholders to Vote July 13 on $7 Million Sale of Stake in Medical Device Retailer
06:25 AM EDT, 06/17/2022 (MT Newswires) -- Shareholders of New Ray Medicine International (HKG:6108) will convene on July 13 to vote on the company's proposed disposal, according to a Friday disclosur
Xinrui Pharmaceutical (06108) granted share options to subscribe for 143.2 million shares.
Zhitong Financial App News, Xinrui Pharmaceutical (06108) announced that on June 14, 2022, the company has granted share options to a number of eligible persons under the share option Scheme to subscribe for a total of 143.2 million ordinary shares of HK $0.050 each in the company's share capital, subject to acceptance by the grantee. The exercise price is HK $0.287 per share.
06108.HK has granted a total of 143.2 million share options
06108.HK announced that on June 14th, 2022, the company has granted share options to a number of eligible persons under the share option scheme to subscribe for a total of 143.2 million ordinary shares of HK $0.050 each in the company's share capital.
Changes in Hong Kong stocks | recently active pharmaceutical penny stocks plummeted in the afternoon. Cutting edge Pharmaceuticals (06108) fell more than 70%. Tailing Pharmaceutical (01011) fell more than 20%.
Recently, market funds focused on some pharmaceutical penny stocks, and related stocks plummeted this afternoon. As of press time, Xinrui Pharmaceutical (06108) fell 68.6% to HK $0.275, with a turnover of HK $268 million; Tailin Pharmaceuticals (01011) fell 18.67% to HK $0.183, with a turnover of HK $41.2485 million. Zhitong Finance previously pointed out that the sharp rise in the company's performance was mainly due to the sharp increase in the company's performance, as well as getting rid of the negative impact of the acquisition a few years ago. "it all started with the resumption of trading in Xinrui Pharmaceutical (06108)," Zhitong Finance said earlier.
Changes in Hong Kong stocks | Xinrui Pharmaceuticals (06108) rose 46% in early trading and turned down more than 30% in the afternoon.
Xinrui Pharmaceuticals (06108) rose more than 46 per cent in early trading before its shares fluctuated sharply, falling more than 30 per cent in the afternoon and more than 77 per cent throughout the day. As of press time, it fell 28.57% to HK $0.90, with a turnover of HK $1.178 billion. Zhitong Financial APP had previously soared 600% in 10 days, and it all started with the resumption of trading of Xinrui Pharmaceutical (06108). It was pointed out that the sharp rise in Xinrui Pharmaceutical was mainly due to the substantial growth in the company's performance and getting rid of the negative impact of the acquisition a few years ago. However, from the perspective of fundamentals, the future prospects of pharmaceutical distributors are not optimistic.
Changes in Hong Kong stocks | active trading shares of Xinrui Pharmaceutical (06108) soared by more than 45% and accumulated by more than 160% in the past three days.
New sharp medicine (06108) continues to be active recently, rising more than 45% in early trading and more than 160% in the past three days. As of press time, it rose 46.03% to HK $1.84, with a turnover of HK $183 million. On the news side, the new sharp medicine annual results show that in 2021, the new sharp medicine realized revenue increased 1.52 times year-on-year to about 335 million Hong Kong dollars, a loss of about 2.82 million yuan, narrowing about 96% year-on-year. The company stressed that the increase in sales of second-generation cephalosporins is the main reason for the big increase in revenue. Zhitong Financial APP previously soared 600% in 10 days, everything from cutting-edge medicine.
Changes in Hong Kong stocks | Xinrui Pharmaceutical (06108) rose 50% against the market. Individual shareholder Wen Xiaodong pushed the stock price changes recently.
Xinrui Pharmaceuticals (06108), a popular small-cap stock, was active against the market in early trading, up about 50 per cent. In the middle and late last month, Xinrui Pharmaceuticals rose tenfold in the short term, while from April 25 to this week saw a deep adjustment, with shares down 70% from their highs. During the change period, Xinrui Pharmaceutical was deeply involved by individual shareholder Wen Xiaodong and became the driver of recent stock price fluctuations. As of press time, Xinrui Pharmaceutical rose 45.57% to HK $1.15, with a turnover of HK $45 million. Data from the Stock Exchange show that on March 28th, Wen Xiaodong bought nearly 43 million shares and increased his shareholding to 97 million shares.
Xinrui Pharmaceutical (06108.HK) lost 5.104 million shares by shareholder Wen Xiaodong.
Gronghui APP learned that according to the latest equity disclosure information of the Stock Exchange, on May 3, 2022, Xinrui Pharmaceutical (06108.HK) was reduced by shareholder Wen Xiaodong at an average price of HK $0.9921 per share, involving a capital of about HK $5.0637 million. After the reduction, Wen Xiaodong's latest number of shares is 466760000 shares, and the proportion of shares has dropped from 28.22% to 27.92%.
Don't Ignore The Fact That This Insider Just Sold Some Shares In New Ray Medicine International Holding Limited (HKG:6108)
We note that a New Ray Medicine International Holding Limited (HKG:6108) insider, Shenglei Qian, recently sold HK$154k worth of stock for HK$1.92 per share. However we note that the sale only shru
Cutting-edge Medicine: report 2021
Loading...
No Stock Yet